Inclusion is bigger than policy or workplace acronyms. It’s a way of living and fostering greater outcomes, writes Novo ...

Pharma and biotech companies can use AI to effectively and efficiently communicate with providers and patients, writes Jenna ...

Royalty-bearing license agreements are a cornerstone of commercialization in the life sciences and technology industries. Companies often use them to expand their business into new markets while ...

Since the start of his second term, President Trump has shown a clear commitment to improving access to medicines for American patients. In late September 2025, his Administration reaffirmed this ...

This article is the third and final installment of a three-part series aimed at helping drug and device manufacturers better navigate the VA and DoD health systems. Click here to read part one of the ...

In the pharmaceutical industry, regulatory affairs (RA) and pharmacovigilance (PV) are often viewed as separate entities with distinct responsibilities. RA navigates the complex landscape of drug ...

The Business of Biotech was taped in front of a live audience in Boston during the BIO conference last month, and we couldn’t have asked for a better guest to test out this new format. Amber Salzman, ...

Amid recent and proposed sweeping cuts to federal research funding, ranging from suspended federal funding to universities and research facilities to updated policy by the NIH (NIH) to reduce indirect ...

The annual BIO International Convention, held this year in Boston on June 16 through 19, is a choose-your-own-adventure kind of meeting. With educational programing, theme-based session tracks, one-on ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...

A revolution is coming in the U.S. generics marketplace, one that players in the space ignore at their peril. This revolution has the potential to transform savvy organizations into engines of growth, ...

Patient safety is the top priority for regulators. While the industry and the public advocate for alternatives to animal testing, regulators require strong evidence that alternatives are equally safe ...